Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AbbVie : Seeks U.S., European OK of Rinvoq in Eczema

10/19/2020 | 10:39am EST

By Colin Kellaher

AbbVie Inc. on Monday said it has filed with the U.S. Food and Drug Administration and the European Medicines Agency for expanded approval of Rinvoq for the treatment of adults and adolescents with moderate to severe atopic dermatitis, a chronic, inflammatory skin disease more widely known as eczema.

The North Chicago, Ill., biopharmaceutical company said the applications are supported by data from three pivotal phase 3 studies in which Rinvoq showed significant improvement in skin clearance and reduction in itch compared with placebo.

AbbVie last year received U.S. and European approval for Rinvoq for adults with moderately to severely active rheumatoid arthritis. The company in August filed for U.S. and European approval for the drug in adults with active ankylosing spondylitis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-19-20 1038ET

All news about ABBVIE INC.
11/25ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
AQ
11/24ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
PR
11/19ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
AQ
11/18ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
PR
11/18Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
RE
11/17S&P, Dow futures retreat as coronavirus cases spike
RE
11/17ABBVIE : Allergan Aesthetics Celebrates Second Annual BOTOX Cosmetic Day
AQ
11/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 45 625 M - -
Net income 2020 12 365 M - -
Net Debt 2020 74 478 M - -
P/E ratio 2020 25,6x
Yield 2020 4,50%
Capitalization 185 B 185 B -
EV / Sales 2020 5,69x
EV / Sales 2021 4,63x
Nbr of Employees 47 000
Free-Float 98,5%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 111,43 $
Last Close Price 104,89 $
Spread / Highest target 21,1%
Spread / Average Target 6,23%
Spread / Lowest Target -7,52%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.17.69%185 181
JOHNSON & JOHNSON-1.28%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.0.30%203 048
MERCK & CO., INC.-11.97%202 555